Orgenesis
Orgenesis is dedicated to unlocking the potential of cell and gene therapies (CGTs) through engineering and collaboration. They aim to drastically lower costs for higher quality, standardized CGTs, regardless of patient location, by providing a globally harmonized and decentralized CGT manufacturing infrastructure. Their mission is to make advanced therapies accessible, affordable, and effective by developing innovative platforms like the POCare Platform, which simplifies and scales up the production of personalized cell and gene therapies at the point of care. With a focus on collaboration with industry partners, academia, hospitals, and research institutes worldwide, Orgenesis strives to bring promising therapeutics to market efficiently and cost-effectively, ultimately improving patient outcomes globally.
Industries
Nr. of Employees
medium (51-250)
Orgenesis
White Plains, New York, United States, North America
Products
Autologous CD19-targeted CAR-T for B-ALL and lymphoma
Development program for an autologous CAR-T therapy targeting CD19 intended to treat relapsed or refractory B-cell acute lymphoblastic leukemia and lymphoma.
Bi-specific CD19/22 CAR-T for relapsed B-ALL
Development of a bi-specific CAR-T construct targeting CD19 and CD22 to reduce relapse risk in B-cell acute lymphoblastic leukemia.
CAR-NK and other adoptive cell therapies (multiple oncology indications)
Programs for natural killer cell-based therapies and other adoptive cell approaches being developed for hematologic and solid tumor indications.
Tumor-infiltrating lymphocyte (TIL) expansion platform
Adoptive cell therapy platform using expansion of autologous tumor-infiltrating lymphocytes with an associated biomanufacturing process that includes metabolic-sensor-driven harvest optimization.
Cellular vaccines and APC-based cancer vaccines
Development of cellular vaccine approaches using patient antigen-presenting cells pulsed with tumor antigens to elicit broad anti-tumor immune responses.
Ribonuclease-based antiviral formulations (topical and systemic)
Programs developing topical and systemic formulations of RNA-degrading enzymes intended as broad-spectrum antivirals for indications including HPV-related lesions and respiratory viral syndromes.
Autologous CD19-targeted CAR-T for B-ALL and lymphoma
Development program for an autologous CAR-T therapy targeting CD19 intended to treat relapsed or refractory B-cell acute lymphoblastic leukemia and lymphoma.
Bi-specific CD19/22 CAR-T for relapsed B-ALL
Development of a bi-specific CAR-T construct targeting CD19 and CD22 to reduce relapse risk in B-cell acute lymphoblastic leukemia.
CAR-NK and other adoptive cell therapies (multiple oncology indications)
Programs for natural killer cell-based therapies and other adoptive cell approaches being developed for hematologic and solid tumor indications.
Tumor-infiltrating lymphocyte (TIL) expansion platform
Adoptive cell therapy platform using expansion of autologous tumor-infiltrating lymphocytes with an associated biomanufacturing process that includes metabolic-sensor-driven harvest optimization.
Cellular vaccines and APC-based cancer vaccines
Development of cellular vaccine approaches using patient antigen-presenting cells pulsed with tumor antigens to elicit broad anti-tumor immune responses.
Ribonuclease-based antiviral formulations (topical and systemic)
Programs developing topical and systemic formulations of RNA-degrading enzymes intended as broad-spectrum antivirals for indications including HPV-related lesions and respiratory viral syndromes.
Services
Point-of-care manufacturing deployment
Deployment and operation of mobile and regional point-of-care processing units to enable onsite production of personalized therapies.
Process development and QC validation services
Process development services focused on quality control, validation, and harmonization to support therapy commercialization.
Technology customization and integration
Customization and validation of automated processing systems and closed processing technologies for specific therapies.
Network partnership and collaborative clinical research
Coordination of collaborative research, clinical trials and partner networks to enable distributed development, validation, and production.
Training and centralized data management services
Provision of standardized training programs and centralized IT/data management solutions for harmonized operations and QA across sites.
Point-of-care manufacturing deployment
Deployment and operation of mobile and regional point-of-care processing units to enable onsite production of personalized therapies.
Process development and QC validation services
Process development services focused on quality control, validation, and harmonization to support therapy commercialization.
Technology customization and integration
Customization and validation of automated processing systems and closed processing technologies for specific therapies.
Network partnership and collaborative clinical research
Coordination of collaborative research, clinical trials and partner networks to enable distributed development, validation, and production.
Training and centralized data management services
Provision of standardized training programs and centralized IT/data management solutions for harmonized operations and QA across sites.
Expertise Areas
- Point-of-care cell and gene therapy manufacturing
- Autologous cell therapy development (CAR-T, CAR-NK, TIL)
- Closed and automated bioprocessing systems
- GMP manufacturing and QA/QC
Key Technologies
- Closed-loop bioprocessing units
- Automated single-use sensor integration
- Cloud-based batch monitoring and traceability
- Metabolic sensors for cell harvest optimization